GlassScriptPhysician profile
Aashish Bharara
NPI 1881842268
$2,714.85
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $1,045 · 2021: $413 · 2022: $494 · 2023: $180 · 2024: $39.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $446.01 | 2022-2023 | Senza |
| Allergan, INC. | $249.85 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $201.22 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $189.29 | 2019-2021 | |
| Amgen INC. | $186.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $148.00 | 2020 | |
| Smith+Nephew, INC. | $109.87 | 2021-2022 | |
| Ucb, INC. | $95.15 | 2019-2020 | |
| Eisai INC. | $94.24 | 2019-2020 | |
| Radius Health, INC. | $81.89 | 2021-2022 | |
| Abbott Laboratories | $67.11 | 2022 | |
| Kyowa Kirin, INC. | $58.10 | 2019-2020 | |
| Csl Behring | $55.56 | 2020 | |
| Abbvie INC. | $55.07 | 2023 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $54.38 | 2019-2024 | Varithena Administration Pack |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theragen, INC. | $52.26 | 2021 | |
| Avanir Pharmaceuticals, INC. | $51.02 | 2019-2020 | |
| Bausch Health US, LLC | $47.18 | 2019-2020 | |
| Acorda Therapeutics, INC | $44.60 | 2020 | |
| Axogen | $35.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $31.67 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.55 | 2020 | |
| Vertical Pharmaceuticals, LLC | $28.00 | 2019 | |
| Zyla Life Sciences, INC. | $27.40 | 2019 | |
| Merck Sharp & Dohme LLC | $26.80 | 2020 | |
| Zimmer Biomet Holdings, INC. | $26.09 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.92 | 2020 | |
| Tersera Therapeutics LLC | $23.40 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.16 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2020 | |
| Biogen, INC. | $15.74 | 2019 | |
| Horizon Therapeutics Plc | $15.70 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $15.63 | 2020 | |
| Currax Pharmaceuticals LLC | $15.13 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2019 | |
| Hydrofera LLC | $14.82 | 2023 | Cutimed Sorbact |
| Saol Therapeutics INC. | $14.52 | 2019 | |
| Ge Healthcare | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aashish Bharara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.